Net profit of Glenmark Pharmaceuticals rose 15.88% to Rs 403.21 crore in the quarter ended December 2025 as against Rs 347.96 crore during the previous quarter ended December 2024. Sales rose 17.75% to Rs 3888.00 crore in the quarter ended December 2025 as against Rs 3301.90 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales3888.003301.90 18 OPM %22.3718.18 - PBDT872.79579.06 51 PBT718.34456.33 57 NP403.21347.96 16 Powered by Capital Market - Live News

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 30 January 2026.Powered by Capital Market - Live News

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. Glenmark`s Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) of BPI Labs, LLC, NDA 205029. Powered by Capital Market - Live News

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial. Glenmark`s Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Leucovorin Calcium for Injection, 350 mg/vial, of Hospira, Inc. [NDA 008107]. Glenmark will begin distribution in December 2025.Powered by Capital Market - Live News

Glenmark Pharmaceuticals announced that the U.S. Food and Drug Administration (U.S. FDA) completed Pre-Approval Inspection at the Company`s formulations manufacturing facility in Chhatrapati Sambhajinagar (Aurangabad). The inspection was carried out from 24 November to 28 November 2025, and concluded with zero 483 observations. Powered by Capital Market - Live News